We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christian Meyhoff

Christian S Meyhoff MD, PhD

Chief Physician in Anaesthesiology and Head of Research at Department of Anaesthesia and Intensive Care, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Associate Professor at University of Copenhagen.

Christian S. Meyhoff, MD, PhD is Chief Physician in Anaesthesiology and Head of Research at Department of Anaesthesia and Intensive Care, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. He holds a position as Associate Professor at University of Copenhagen.

Dr. Meyhoff has since 2005 conducted several major randomized clinical trials, primarily about the effects of hyperoxia and cardiovascular outcomes. He was the principal investigator of the PROXI trial (PeRioperative OXygen fraction and Infections after abdominal surgery, 1,400 patients at 14 Danish hospitals, JAMA 2009;302:1543-50). Among other RCTs, this lead to his PhD thesis entitled “Anaesthesia for the obese patient - with special emphasis on propofol, rocuronium and inspiratory oxygen fraction” in 2009 under the mentorship of Prof. Lars S. Rasmussen. His interest in long-term outcomes after anaesthesia has resulted in follow-up studies of the PROXI trial about long-term mortality (Anesth Analg 2012;115:849-54), risk of new or recurrent cancer (BJA 2014;113:i74-81), and myocardial infarction (Int J Cardiol 2016;215:238-43).

Together with the PROXI Trial Group, Dr. Meyhoff has challenged the assumption that hyperoxia during abdominal surgery reduces the risk of surgical site infection without any side effects. His group’s recent publications demonstrate, on the contrary, that the risk reduction in surgical site infection is minimal at most, and that hyperoxia may be associated with several significant long-term risks.

Dr. Meyhoff has considerable experience in international RCTs through collaboration with Population Health Research Institute (PHRI). The collaboration includes the national leadership in Denmark of the POISE-2 trial (PeriOperative ISchemic Evaluation-2 Trial, 10,010 patients, of which 321 were included at two Danish hospitals, NEJM 2014;370:1494-503 and NEJM 2014;370:1504-13) and the MANAGE trial (Management of Myocardial Injury After Noncardiac Surgery Trial, 1,754 patients, of which 120 were included at 6 Danish hospitals, Lancet 2018;391:2325-34).

Dr. Meyhoff is working 50% as clinical anaesthesiologist and 50% as research leader. His research group holds a number of significant national grants that allows growth and participating with adequate manpower in several international RCTs. Dr. Meyhoff’s research group has close collaboration with several other high-volume departments of anaesthesiology in Denmark and Scandinavia.

Disclosures

COI: As Head of Research, his department receives direct and indirect research funding from Ferring Pharmaceuticals, Merck Sharp & Dohme, and Boehringer Ingelheim for research outside perioperative oxygen therapy.